An interventional study of Food supplement (T1675) and Placebo in Endometriosis (Diagnosis), sponsored by Arafarma Group, S.A.. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Arafarma Group, S.A. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Endometriosis with a site in Spain — 13 open to participants now, 15 under way, none of them phase 3. Endometriosis · Spain.
Among the 42 studies in Endometriosis with a site in Spain, this one is the 21st largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 40th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →13 of the 42 studies in Endometriosis with a site in Spain are open now. Recruiting first, the newest first:
Francisco Algaba Chueca · Sites in Spain
Ages 18–45 · Women only · Healthy volunteers
University of Seville · Sites in Spain
Ages 18+ · Women only
Fundacion Dexeus · Sites in Spain
Ages 18+ · Women only
Hospital Universitari de Bellvitge · Sites in Spain
Ages 18–45 · Women only
University of Valencia · Sites in Spain
Ages 18–45 · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 90 across the 33 interventional studies, 70 across the 8 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 42 have an industry lead sponsor. The 10 most frequent:
Arafarma Group, S.A. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Arafarma Group, S.A. has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Endometriosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07270393Biogipuzkoa Health Research InstituteStudy of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis. | 2026-12-01 |
| NCT06955221Hospital Universitari de BellvitgeEffect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis | 2026-12-31 |
| NCT06024109Aesculap AGPerformance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy | 2027-01 |
| NCT06876376Fundacion DexeusIntraoperative Ultrasound in Bowel Deep Endometriosis | 2027-02 |
| NCT07393958Arafarma Group, S.A.Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain. | 2027-08-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 42 studies in Endometriosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.
Patients included into the study will be randomized into two treatment groups (30:30 patients). 30 patients will be treated with the food supplement and 30 patients will be treated with placebo. Both groups will be stratified by the presence or absence of hormonal therapy. Patients will be required to attend 6 study visits (selection visit, baseline or visit 0, and visits 1, 2, 3 and final or visit 4). Patients will complete a daily endometriosis symptom diary, which also includes a record of anti-inflammatory and paing medication use. Study treatment will be administred at Visit 0 or Baseline until Visit 4 or Final. At the study visits, patients will be requested to confirm the pain intensity through the VAS scale for different endometriosis pain types. They will be also requested to complete several questionnaires about quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient takes one buccal tablet per day.
Dietary Supplement: Food supplement (T1675)
Patient takes one buccal tablet per day.
Other: Placebo
Doliral is the food supplement, which is the investigational product at this study.
Placebo is the control treatment.
To measure the improvement of the quality of life.
Patients complete EQ-5D-5L questionnaire at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). This questionnaire measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression and health status. These five dimensions have 5 response levels: No problems, slight problems, moderate problems, severe problems and extreme problems. This questionnaire also has a Visual Analogue Scale from 0 (worse health status) to 100 (best health status).
Time frame: From baseline visit to the final visit at 12 weeks.
To measure the improvement of the quality of life.
Patients complete the Endometriosis Health Profile 30 Questionnaire at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). This questionnaire evaluates six domains: pain, control and powerlessness, emotional well-being, social support and self-image. These scales are converted into a 0-100 score, 0 is best health status and 100 is worse quality of life.
Time frame: From baseline visit to the final visit at 12 weeks.
To measure the improvement of the quality of life.
Patients complete PGI-I (Patient Global Impression of Improvement) scale at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). PGI-I is a Likert scale from 1 (significantly better) to 7 (significantly worse).
Time frame: From baseline visit to the final visit at 12 weeks.
To measure the improvement in pain intensity.
To describe the type and intensity of pain using a Visual Analogue Scale (VAS) at at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). It is measured the change of these results from baseline visit to the final visit. Also patients complete a symptoms diary between visits. For each symptom, the patient will record intensity (on a scale from 1 to 10).
Time frame: From baseline visit to the final visit at 12 weeks.
Compare the reduction in the need for prescription and dosage of anti-inflammatory and analgesic pharmacological treatment.
Patients will complete the use of inflammatory and analgesic pharmacological treatment (name, dose and time) in a diary between visits.
Time frame: From baseline visit to the final visit at 12 weeks.
To measure the incidence of clinically relevant episodes
To assess and destribe the type, intensity and relationship with investigational product of clinically relevant episodes at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4).
Time frame: From Visit 1 (2 weeks) to Visit 4 or Final (12 weeks).
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.
Of 214 interventional studies with no phase under Endometriosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 17 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Aug 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arafarma Group, S.A.